EP2457919B1 - Oligosaccharides comportant un groupe amino-oxy et conjugués associés - Google Patents

Oligosaccharides comportant un groupe amino-oxy et conjugués associés Download PDF

Info

Publication number
EP2457919B1
EP2457919B1 EP11188504.2A EP11188504A EP2457919B1 EP 2457919 B1 EP2457919 B1 EP 2457919B1 EP 11188504 A EP11188504 A EP 11188504A EP 2457919 B1 EP2457919 B1 EP 2457919B1
Authority
EP
European Patent Office
Prior art keywords
oligosaccharide
group
aminooxy
reactive group
chosen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP11188504.2A
Other languages
German (de)
English (en)
Other versions
EP2457919A1 (fr
Inventor
Yunxiang Zhu
Seng H. Chen
Canwen Jiang
Luis Z. Avial
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Priority to EP23187944.6A priority Critical patent/EP4293112A3/fr
Priority to EP19177425.6A priority patent/EP3597655B1/fr
Priority to SI200832088T priority patent/SI2457919T1/sl
Priority to PL11188504T priority patent/PL2457919T3/pl
Publication of EP2457919A1 publication Critical patent/EP2457919A1/fr
Application granted granted Critical
Publication of EP2457919B1 publication Critical patent/EP2457919B1/fr
Priority to HRP20191562 priority patent/HRP20191562T1/hr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/738—Cross-linked polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04012—Sphingomyelin phosphodiesterase (3.1.4.12)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0102—Alpha-glucosidase (3.2.1.20)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01022—Alpha-galactosidase (3.2.1.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01076—L-Iduronidase (3.2.1.76)

Definitions

  • the invention relates generally to methods for the synthesis of oligosaccharides comprising an aminooxy group from oligosaccharides comprising a reactive group.
  • the disclosure further relates to oligosaccharides comprising an aminooxy group.
  • the disclosure also relates to methods of conjugating oligosaccharides comprising an aminooxy group to proteins, including glycoproteins (such as, e.g., lysosomal enzymes), and to compositions of oligosaccharide-protein conjugates, including oligosaccharide-glycoprotein conjugates.
  • Another embodiment of the disclosure relates to methods of treating lysosomal storage disorders using such oligosaccharide-lysosomal enzyme conjugates.
  • Lysosomal storage disorders are a class of rare metabolic disorders comprising over forty genetic diseases involving a deficiency in the activity of lysosomal hydrolases.
  • a hallmark feature of LSDs is the abnormal accumulation of lysosomal metabolites, which leads to the formation of large numbers of distended lysosomes.
  • LSDs can be treated by administration of the active version of the enzyme deficient in the patient, a process termed enzyme replacement therapy (ERT).
  • ERT enzyme replacement therapy
  • the administered replacement enzyme bearing a terminal mannose-6-phosphate (M6P) is taken up by target cells through cell-surface-associated cation-independent M6P receptor (CI-MPR)-mediated endocytosis, and directed to the lysosome.
  • M6P mannose-6-phosphate
  • CI-MPR cell-surface-associated cation-independent M6P receptor
  • U.S. Patent No. 7,001,994 describes a method for coupling oligosaccharides comprising M6P with glycoproteins.
  • the oligosaccharides of the glycoproteins are first oxidized with periodate or galactose oxidase to result in the formation of carbonyl groups, which are then chemically conjugated with an oligosaccharide functionalized at the reducing end with a carbonyl-reactive group (such as, e.g., a hydrazine, hydrazide, aminooxy, thiosemicarbazide, semicarbazide, or amine group) to yield an oligosaccharide-glycoprotein conjugate.
  • a carbonyl-reactive group such as, e.g., a hydrazine, hydrazide, aminooxy, thiosemicarbazide, semicarbazide, or amine group
  • a conjugate of the lysosomal enzyme acid ⁇ -glucosidase (GAA) with a bis-M6P oligosaccharide was prepared by the above-described method, and found to be more effective in reducing skeletal and cardiac muscle glycogen than recombinant human GAA in a murine model of Pompe disease, an autosomal recessive muscular disease resulting from a metabolic deficiency of GAA, and characterized by the accumulation of lysosomal glycogen.
  • Rodriguez et al. (J. Org. Chem., 1998, 63 (21), 7134-7135 ) relates to aminooxy-, hydrazide-, and thiosemicarbazide-functionalized saccharides as reagents for glycoconjugate synthesis.
  • US 20050169941 relates to a conjugate comprising an amino-oxy homofunctional or heterofunctional reagent and an entity chosen from polysaccharides, oligosaccharides, carbohydrates, and carbohydrate-containing molecules containing at least one carbonyl group, to form a polysaccharide, oligosaccharide, carbohydrate, or carbohydrate-containing molecule functionalized via at least one oxime linkage.
  • Lees et al. (Vaccine, 2006, 24(6), 716-729 ) relates to the synthesis of protein-polysaccharide conjugate vaccines using aminooxy reagents and oxime chemistry
  • Aminooxy groups are particularly useful carbonyl-reactive groups for the conjugation reactions described above, as the resulting conjugates comprise a relatively stable oxime linkage. Therefore, there is a need for methods for the preparation of aminooxy functionalized oligosaccharides.
  • the present invention provides a method of preparing an oligosaccharide comprising an aminooxy group, the method comprising:
  • the present disclosure provides methods of preparing oligosaccharides comprising an aminooxy group. These methods are generally applicable to a broad range of protected and unprotected oligosaccharides, such as, e.g., branched and unbranched, and phosphorylated and unphosphorylated, oligosaccharides.
  • the oligosaccharides may be a disaccharide, trisaccharide, tetrasaccharide, pentasaccharide, hexasaccharide, heptasaccharide, or greater.
  • the oligosaccharide may, in certain embodiments, comprise at least one M6P residue. In some embodiments, the oligosaccharide may comprise at least 1, 2, 3, 4, 5, 6, or 7 terminal M6P residues.
  • the disclosure provides a method of preparing an oligosaccharide comprising an aminooxy group from an oligosaccharide comprising a reactive group.
  • the method comprises:
  • the first and second reactive groups may be chosen from, e.g., hydrazine, hydrazide, thiosemicarbazide, semicarbazide, amine, carboxyl, activated ester, acyl halide, acyl azide, alkyl halide, anhydride, isothiocyanate, isocyanate, and sulfonyl halide groups.
  • the aminooxy compound is chosen from compounds of Formula II : wherein Y is the second reactive group, Z is chosen from alkyl, alkenyl, alkynyl, aryl, heteroaryl, and heterocyclyl, and P is chosen from amino protecting groups (such as, e.g., carbamate protecting groups).
  • Y may be a carboxyl, activated ester, acyl halide (such as, e.g., an acyl fluoride or acyl chloride), acyl azide, alkyl halide, anhydride, isothiocyanate, isocyanate, or sulfonyl halide (such as, e.g., a sulfonyl chloride or sulfonyl bromide).
  • Y may be, e.g., a hydrazine, hydrazide, thiosemicarbazide, semicarbazide, or amine group.
  • the aminooxy compound of Formula II is chosen from compounds of Formula III : wherein Y is the second reactive group, n is chosen from integers ranging from 1 to 10, and P is chosen from amino protecting groups.
  • the aminooxy compound comprises an amino protecting group
  • the method further comprises a step (d), deprotecting the oligosaccharide comprising an aminooxy group.
  • the disclosure further provides an oligosaccharide comprising (1) an aminooxy group and (2) mannose-6-phosphate.
  • that oligosaccharide is prepared by the methods described above.
  • the invention provides an oligosaccharide comprising an aminooxy group of Formula IV : wherein m and p are independently chosen from integers ranging from 1 to 10.
  • the invention provides an oligosaccharide of Formula V :
  • the disclosure provides methods of coupling an oligosaccharide to a protein.
  • the method comprises:
  • the disclosure further provides an oligosaccharide-protein conjugate comprising (1) a protein, (2) an oligosaccharide, and (3) an oxime group connecting the protein and the oligosaccharide.
  • an oligosaccharide-protein conjugate prepared by the methods disclosed above.
  • the oligosaccharide-protein conjugate is an oligosaccharide-glycoprotein conjugate.
  • the oligosaccharide-glycoprotein conjugate is the conjugate of an oligosaccharide comprising at least one M6P and of a lysosomal enzyme such as, e.g., a lysosomal hydrolase.
  • the disclosure provides pharmaceutical compositions comprising an oligosaccharide-protein conjugate of the disclosure.
  • Another embodiment of the disclosure provides methods of treating a lysosomal storage disorder such as, e.g., those disclosed in Table 1.
  • the methods comprise administering to a mammal an oligosaccharide-glycoprotein conjugate of the invention, wherein the oligosaccharide comprises at least one M6P and the glycoprotein is a lysosomal hydrolase.
  • This disclosure further provides the use of a conjugate of the invention for treating a lysosomal storage disorder in a subject in need thereof, and in the manufacture of a medicament for treating a lysosomal storage disorder.
  • an oligosaccharide refers to a disaccharide, trisaccharide, tetrasaccharide, pentasaccharide, hexasaccharide, heptasaccharide, or larger oligosaccharide (such as, e.g., an oligosaccharide comprising 2-50, 2-10, 8-25, or 8-50 saccharide units).
  • an oligosaccharide may be, e.g., a disaccharide, trisaccharide, tetrasaccharide, a pentasaccharide, a hexasaccharide, a heptasaccharide, or a larger oligosaccharide.
  • An oligosaccharide may be mono-, bi-, tri-, tetra-, or penta-antennary in structure.
  • An oligosaccharide may comprise 0, 1, 2, 3, 4, or more branch points.
  • the reactive group on the oligosaccharide also referred to as a first reactive group, may be, in some embodiments, e.g., a hydrazine group, hydrazide group, semicarbazide group, thiosemicarbazide, or amine group.
  • the first reactive group may be, e.g., a carboxyl, ester (such as, e.g., an activated ester), acyl halide (such as, e.g., acyl fluoride or acyl chloride), acyl azide, alkyl halide, anhydride, isothiocyanate, isocyanate, or sulfonyl halide (such as, e.g., sulfonyl chloride or sulfonyl bromide) group.
  • ester such as, e.g., an activated ester
  • acyl halide such as, e.g., acyl fluoride or acyl chloride
  • acyl azide alkyl halide
  • anhydride isothiocyanate
  • isocyanate isocyanate
  • sulfonyl halide such as, e.g., sulfonyl chloride or sul
  • the first reactive group may be connected to the reducing end of the oligosaccharide or may be located anywhere in the oligosaccharide.
  • the first reactive group may, in certain embodiments, be connected through one or more linkers to the oligosaccharide.
  • a linker as used herein, may be chosen from, e.g., a combination of optionally substituted alkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclyl, acyloxy, alkoxy, aryloxy, and heterocyclyloxy groups.
  • a linker may be interrupted or terminated by one or more heteroatoms such as, e.g., nitrogen, sulfur, and oxygen.
  • a linker in some embodiments, may comprise one or more ether, ester, or amide group.
  • linker any chemical group of the linker (such as, e.g., alkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclyl, acyloxy, alkoxy, aryloxy, and heterocyclyloxy) may be substituted or unsubstituted, unless otherwise stated.
  • linker such as, e.g., alkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclyl, acyloxy, alkoxy, aryloxy, and heterocyclyloxy
  • Substituents may be chosen from, e.g., acyl, acylamino, acyloxy, alkenyl, alkoxy, alkyl, alkynyl, amido, amino, aryl, aryloxy, azido, carbamoyl, carboalkoxy, carboxy, cyano, cycloalkyl, formyl, guanidino, halo, heteroaryl, heterocyclyl, hydroxy, iminoamino, nitro, oxo, phosphonamino, sulfinyl, sulfonamino, sulfonate, sulfonyl, thio, thioacylamino, thioureido, and ureido.
  • the substituents may themselves be substituted or unsubstituted, and may be interrupted or terminated by one or more heteroatoms such as, e.g., nitrogen, sulfur, and oxygen.
  • an oligosaccharide may comprise at least one protecting group.
  • protecting group refers to any substituent that may be used to prevent a functional group (such as, e.g., an amine group, a carboxyl group, a hydroxyl group, a hydrazine group, a hydrazide group, a semicarbazide group, or a thiosemicarbazide group) on a molecule from undergoing a chemical reaction while chemical change occurs elsewhere in the molecule.
  • a protecting group can be removed under the appropriate chemical conditions.
  • protecting groups are known to those skilled in the art, and examples of protecting groups, methods for their addition, and methods for their removal can be found in, e.g., Greene et al., Protective Groups in Organic Synthesis, 3rd ed., John Wiley and Sons: New York, 1999 and Kocienski, Protecting Groups, 3rd ed., Georg Thieme Verlag: Stuttgard, Germany, 2005
  • the oligosaccharide may comprise at least one protecting group chosen from hydroxyl protecting groups, carboxyl protecting groups, and amino protecting groups. In other embodiments, an oligosaccharide may be "unprotected," and may not comprise any protecting groups.
  • An oligosaccharide may be isolated from a natural source or may be prepared by chemical or enzymatic synthesis.
  • An oligosaccharide isolated from a natural source may be homogeneous or may be a heterogeneous mixture of related oligosaccharides.
  • an oligosaccharide may be prepared by chemical or enzymatic modification of an oligosaccharide isolated from a natural source ("semi-synthesis").
  • the oligosaccharide may be a synthetic oligosaccharide having the chemical structure of a naturally occurring oligosaccharide.
  • an oligosaccharide may comprise a monosaccharide that is recognized by a particular receptor.
  • the monosaccharide recognized by a particular receptor may be chosen from, e.g., galactose, GalNAc, mannose, M6P, glucose, GlcNAc, sialic acid, or sulfated sialic acid residue.
  • An oligosaccharide may, in certain embodiments, comprise at least one M6P residue, such as, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 M6P residues.
  • the monosaccharide recognized by a particular receptor may be, in some embodiments, a penultimate monosaccharide or a terminal monosaccharide.
  • the monosaccharide recognized by a particular receptor may be a terminal galactose, mannose, M6P, glucose, GlcNAc, or sialic acid residue.
  • An oligosaccharide may, in some embodiments, contain at least 1, 2, 3, 4, 5, 6, 7 terminal M6P residues.
  • the oligosaccharide comprising a reactive group may be an M6P-containing hexasaccharide of Formula la:
  • the oligosaccharide of Formula Ia can be described as butyrylhydrazine-4-yl 6-O-phosphono- ⁇ -D-mannopyranosyl-(1 ⁇ 2)- ⁇ -D-mannopyranosyl-(1 ⁇ 6)- ⁇ -D-mannopyranosyl-(1 ⁇ 6)-[6-O-phosphono- ⁇ -D-mannopyranosyl-(1 ⁇ 2)- ⁇ -D-mannopyranosyl-(1 ⁇ 3)]- ⁇ -D-mannopyranoside.
  • the oligosaccharide comprising a reactive group may be an M6P-containing hexasaccharide of Formula Ib:
  • an aminooxy compound may be any compound comprising an aminooxy group and a second reactive group, wherein the second reactive group may react with a first reactive group on an oligosaccharide to form a covalent bond.
  • the second reactive group may be a carboxyl, ester (such as, e.g., an activated ester), acyl halide (such as, e.g., an acyl fluoride or acyl chloride), acyl azide, anhydride, isothiocyanate, isocyanate, or sulfonyl halide (such as, e.g., a sulfonyl chloride or sulfonyl bromide) group.
  • the second reactive group may be, e.g., a hydrazine group, hydrazide group, semicarbazide group, thiosemicarbazide, or amine group.
  • the nitrogen of the aminooxy group of the aminooxy compound is protected with an amino protecting group.
  • amino protecting groups are known to those skilled in the art, and examples of amino protecting groups, methods for their addition, and methods for their removal can be found in pp. 494-653 of Greene et al., Protective Groups in Organic Synthesis, 3rd ed., John Wiley and Sons: New York, 1999 ; Chapter 8 of Kocienski, Protecting Groups, 3rd ed., Georg Thieme Verlag: Stuttgard, Germany, 2005 ; Bodanszky, Principles of Peptide Synthesis, Springer Verlag: New York, 1993 ; Lloyd-Williams et al., Chemical Approaches to the Synthesis of Peptides and Proteins, CRC Press: Boca Raton, FL, 1997 ; and Stewart et al., Solid Phase Peptide Synthesis, 2nd ed., Pierce Chemical Co.: Rockford, IL, 1984
  • the aminooxy compound is chosen from compounds of Formula II : wherein Y is the second reactive group, Z is chosen from alkyl, alkenyl, alkynyl, heteroaryl, aryl, and heterocyclyl, and P is chosen from amino protecting groups.
  • any chemical group on the aminooxy compound may be substituted or unsubstituted, and may be interrupted by one or more chemical groups, unless otherwise stated.
  • Substituents and interrupting chemical groups may be chosen from, e.g., acyl, acylamino, acyloxy, alkenyl, alkoxy, alkyl, alkynyl, amido, amino, aryl, aryloxy, azido, carbamoyl, carboalkoxy, carboxy, cyano, cycloalkyl, formyl, guanidino, halo, heteroaryl, heterocyclyl, hydroxy, iminoamino, nitro, oxo, phosphonamino, sulfinyl, sulfonamino, sulfonate, sulfonyl, thio, thioacylamino, thioureido, and ureido.
  • the substituents may themselves be substituted or unsubstituted, and may be interrupted or terminated by one or more heteroatoms such as, e.g., nitrogen, sulfur, and oxygen
  • Y may be chosen from, for example: and wherein X is chosen from halogens, azide, acyloxy, alkoxy, aryloxy, heteroaryloxy, and heterocyclyloxy.
  • the aminooxy compound is an activated ester.
  • an activated ester is an ester that reacts to form an amide bond under mild conditions.
  • an activated ester is an ester of a relatively acidic alcohol.
  • the aminooxy compound of Formula II is an activated ester of formula and X is chosen from alkoxy, aryloxy, heteroaryloxy, and heterocyclyloxy.
  • X may be chosen from: and
  • Y is chosen from, e.g., hydrazide, hydrazine, thiosemicarbazide, semicarbazide, and amine groups.
  • Z may comprise, for example, a carbonyl, ether, ester, or amide group.
  • Z may be, for example, alkyl interrupted by one or more heteroatoms, such as an oligoethyleneglycol.
  • Z may be monoethyleneglycol, diethyleneglycol, triethyleneglycol, tetraethyleneglycol, or larger oligoethyleneglycol.
  • Z may be, for example, alkyl substituted with oxo and interrupted by one or more heteroatoms, such as an oligopeptide.
  • the oligopeptide may comprise one, two, three, four, five, six, or more component amino acids.
  • the amino acids may be, for example, ⁇ -amino acids, ⁇ -amino acids, ⁇ -amino acids, ⁇ -amino acids, and ⁇ -amino acids.
  • An amino acid may have R or S chirality at any chiral atom.
  • amino acid may be chosen from, e.g., alanine, ⁇ -atanine, ⁇ -aminoadipic acid, 2-aminobutanoic acid, 4-aminobutanoic acid, 1-aminocyclopentanecarboxylic acid, 6-aminohexanoic acid, 2-aminoheptanedioic acid, 7-aminoheptanoic acid, 2-aminoisobutyric acid, aminomethylpyrrole carboxylic acid, 8-amino-3,6-dioxa-octanoic acid, aminopiperidinecarboxylic acid, 3-amino-propionic acid, aminoserine, aminotetrahydropyran-4-carboxylic acid, arginine, asparagine, aspartic acid, azetidine carboxylic acid, benzothiazolylalanine, butylglycine, carnitine, 4-chlorophenylalanine, citrulline, cycl
  • P may be chosen from amino protecting groups known to those of skill in the art.
  • P may be a carbamate protecting group, such as, e.g., a (9-fluorenylmethyl)carbamate (Fmoc), (tert-butyloxy)carbamate (t-Boc), (trichloroethyl)carbamate (Troc), or allylcarbamate (Alloc) protecting group.
  • P may be a non-carbamate protecting group, such as, e.g., an amide protecting group such as a phthalimide or a trifluoroacetamide protecting group.
  • the aminooxy compound of Formula II is chosen from compounds of Formula III : wherein Y and P are as disclosed above, and n is chosen from integers ranging from 1 to 10.
  • n may be chosen from integers from the following ranges: 1-4, 2-6, 2-8, 3-6, and 4-10. In illustrative embodiments, n is 1.
  • the aminooxy compound is t-Boc-aminooxy acetic acid tetrafluorophenyl ester, the structure of which is depicted below.
  • the aminooxy compound has the structure depicted below.
  • the disclosure provides a method of preparing an oligosaccharide comprising an aminooxy group from an oligosaccharide comprising a reactive group.
  • the method comprises:
  • the oligosaccharide comprising a first reactive compound may be, e.g., any oligosaccharide comprising a reactive group as described supra.
  • the oligosaccharide comprising a first reactive group is an oligosaccharide of Formula Ia or an oligosaccharide of Formula Ib .
  • the aminooxy compound comprising a second reactive group may be any aminooxy compound comprising a reactive group, as described supra.
  • first reactive group and “second reactive group,” as used herein, do not denote any particular experimental sequence.
  • step (c) reacting the first reactive group of the oligosaccharide with the second reactive group of the aminooxy compound, may be accomplished by any order of addition of the reactants.
  • the oligosaccharide comprising a first reactive group may be added to the aminooxy compound comprising the second reactive group, or vice versa.
  • both the oligosaccharide and the aminooxy compound may be added simultaneously to a reaction vessel.
  • Step (c) may occur under any suitable conditions (e.g., solvent and temperature) known to those of ordinary skill in the art.
  • one or more additional reagents such as, e.g., coupling reagents and catalysts, may be present during step (c).
  • a coupling reagent is a reagent that may be used to form a covalent bond between the first reactive group and the second reactive group.
  • the reaction conditions may comprise a coupling reagent.
  • Coupling reagents may be chosen from, e.g., phosphonium coupling reagents such as, e.g., BOP (benzotriazole-1-yl-oxy-tris-(dimethylamino)-phosphonium hexafluorophosphate), PyBOP® (benzotriazole-1-yl-oxy-tris-pyrrolidino-phosphonium hexafluorophosphate), and PyBroP® (bromo-tris-pyrrolidino-phosphonium hexafluorophosphate), and from aminium (uronium) coupling reagents such as, e.g., HBTU (2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate), and from aminium (uronium) coupling reagents such as, e.g.
  • Coupling reagents may also be chosen from, e.g., carbodiimide coupling reagents such as, e.g., DIC (1,3-diisopropylcarbodiimide), CDI (1,1' carbonyl diimidazole), and EDC (1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide).
  • carbodiimide coupling reagents such as, e.g., DIC (1,3-diisopropylcarbodiimide), CDI (1,1' carbonyl diimidazole), and EDC (1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide).
  • the coupling reagent is EDC.
  • the reaction conditions comprise both a coupling reagent and a catalyst.
  • the reaction conditions may, in certain embodiments, comprise a catalyst.
  • the catalyst may be chosen from any suitable catalyst known to those of skill in the art, such as, e.g., DHBt-OH (3-hydroxy-1,2,3-benzotriazin-4(3H)-one), HOBt (N-hydroxybenzotriazole), DMAP (4-dimethylaminopyridine), NHS (N-hydroxysuccinimide), N-hydroxysulfosuccinimide, HONB (N-hydroxy-5-norbornene-endo-2,3-dicarboximide), or a tetrabutylammonium salt such as, e.g., TBAI (tetrabutylammonium iodide).
  • the reaction conditions comprise the catalyst DHBt-OH or the catalyst NHS.
  • step (c), reacting the first reactive group of the oligosaccharide with the second reactive group of the aminooxy compound results in the formation of an amide bond.
  • Conditions suitable for the formation of an amide bond are well known to those of ordinary skill in the art, and are described in, e.g., Chan et al., eds., Fmoc Solid Phase Peptide Synthesis: A Practical Approach, Oxford University Press: New York, 2000 ; Bodanszky, Principles of Peptide Synthesis, Springer Verlag: New York, 1993 ; Lloyd-Williams et al., Chemical Approaches to the Synthesis of Peptides and Proteins, CRC Press: Boca Raton, FL, 1997 ; and the Novabiochem® (San Diego, CA) Catalog.
  • the aminooxy compound comprises an amino protecting group
  • the method comprises a further step (d), deprotecting the oligosaccharide comprising an aminooxy group to remove the amino protecting group.
  • Deprotection may occur under any suitable conditions known to those of skill in the art, such as, e.g., those taught in pp. 494-653 of Greene et al., Protective Groups in Organic Synthesis, 3rd ed., John Wiley and Sons: New York, 1999 and Kocienski, Protecting Groups, 3rd ed., Georg Thieme Verlag: Stuttgard, Germany, 2005
  • An illustrative embodiment of the method of the invention provides a method of preparing an M6P-containing oligosaccharide comprising an aminooxy group.
  • the method comprises:
  • Y in Formula III is where X is chosen from hydroxy, aryloxy, heteroaryloxy, and heterocyclyloxy.
  • X is chosen from hydroxy, aryloxy, heteroaryloxy, and heterocyclyloxy.
  • X is
  • the aminooxy compound is In certain embodiments, the first reactive group of the oligosaccharide may be reacted with the second reactive group of the aminooxy compound in the presence of a coupling agent, such as, e.g., EDC, and/or a catalyst, such as, e.g., DHBt-OH.
  • a coupling agent such as, e.g., EDC
  • a catalyst such as, e.g., DHBt-OH.
  • Y in Formula III is a hydrazine, hydrazide, aminooxy, thiosemicarbazide, semicarbazide, or amine group. In certain embodiments, Y in Formula III is
  • the aminooxy compound is In certain embodiments, the first reactive group of the oligosaccharide may be reacted with the second reactive group of the aminooxy compound in the presence of a coupling agent, such as, e.g., EDC, and/or a catalyst, such as, e.g., NHS.
  • a coupling agent such as, e.g., EDC
  • a catalyst such as, e.g., NHS.
  • the present disclosure also provides oligosaccharides comprising an aminooxy group.
  • the disclosure provides oligosaccharides comprising an aminooxy group prepared by the methods disclosed above.
  • the oligosaccharide comprising an aminooxy group may comprise, for example, at least 2, 3, 4, 5, 6, or more monosaccharides, including, e.g., at least one galactose, GalNAc, mannose, M6P, glucose, GlcNAc, sialic acid, or sulfated sialic acid residue.
  • Such an oligosaccharide may be mono-, bi-, tri-, tetra-, or penta-antennary in structure, and may contain 0, 1, 2, 3, 4, or more branch points.
  • the present disclosure provides an oligosaccharide comprising (1) an aminooxy group and (2) mannose-6-phosphate.
  • the oligosaccharide comprising an aminooxy group may, in some embodiments, comprise, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 M6P residues. In some embodiments, the oligosaccharide comprising an aminooxy group may comprise at least 1, 2, 3, 4, or more terminal or penultimate M6P residues.
  • oligosaccharides comprising an aminooxy group are, in certain embodiments, chosen from oligosaccharides of Formula IV : wherein m and p are independently chosen from integers ranging from 1 to 10. For example, in certain embodiments, m and p may be independently chosen from integers selected from the following ranges: 1-4, 2-6, 2-8, 3-6, and 4-10. In illustrative embodiments, m is 3 and p is 1.
  • the aminooxy group is directly linked to the reducing end of the oligosaccharide.
  • the oligosaccharide comprising an aminooxy group may be an oligosaccharide of Formula V :
  • the oligosaccharide to be conjugated with a protein may be chosen from any oligosaccharide comprising a reactive group, as discussed supra, and from any oligosaccharide comprising an aminooxy group, as discussed supra.
  • the oligosaccharide to be conjugated may be an oligosaccharide of Formula Ia , Formula Ib , Formula IV or Formula V .
  • the conjugation methods described herein are broadly applicable to any pure protein, partially purified protein, or fragment thereof, having at least one carbonyl group (where a carbonyl group is a ketone or an aldehyde), including isolated proteins and recombinantly or synthetically produced proteins.
  • the terms "pure,” “purified,” and “isolated” refer to a molecule that is substantially free of its natural environment. For instance, a pure protein is substantially free of cellular material and/or other proteins from the cell or tissue source from which it is derived. The term refers to preparations that are, for example, at least 70% to 80%, 80% to 90%, 90 to 95%; or at least 95%, 96%, 97%, 98%, 99%, or 100% (w/w) pure.
  • the protein may be an enzyme that has optimal activity, as measured by an activity assay, at a pH ranging from 1-7, such as, e.g., 1-3, 2-5, 3-6, 4-5, 5-6, or 4-6.
  • the enzyme may have a pH optimum at a pH ranging from 4-6.
  • the protein may be an enzyme that has an isoelectric point (pI), ranging from 1 to 8, such as, e.g., from 1-3, 2-5, 3-8, 4-5, 5-6, 4-6, 5-8, 6-8, or 7-8.
  • pI isoelectric point
  • the pI of a protein may be measured using, e.g., isoelectric focusing gel electrophoresis.
  • the protein containing a carbonyl group is obtained by the use of an expression system having an expanded genetic code, as described in, e.g., Wang et al., Proc. Natl. Acad. Sci. USA 100:56-61 (2003 ).
  • the carbonyl group may be located on amino acid side chain, as translated.
  • the protein having at least one carbonyl group is a protein having at least one oligosaccharide (i.e., a glycoprotein).
  • a glycoprotein having at least one carbonyl group may be obtained by oxidation of that glycoprotein by any means known to those of skill in the art.
  • a glycoprotein having at least one carbonyl group may be obtained by oxidation of that glycoprotein with periodate (e.g., sodium periodate) or with galactose oxidase.
  • the carbonyl group may be located at a protein glycosylation site.
  • the protein having at least one carbonyl group is a glycoprotein, such as a therapeutic glycoprotein.
  • a therapeutic glycoprotein may be targeted to the lysosome by conjugation with an oligosaccharide comprising mannose-6-phosphate.
  • the glycoprotein may be a lysosomal enzyme, including an ERT enzyme.
  • the enzyme may be a lysosomal hydrolase, including those listed in Table 1.
  • the lysosomal hydrolase is chosen from, e.g., ⁇ -glucosidase, ⁇ -galactosidase A, and acid sphingomyelinase.
  • the lysosomal hydrolase is GAA.
  • Table 1 Examples of LSDs and Corresponding Lysosomal Hydrolases Lysosomal Storage Disorder Defective Enzyme Fabry ⁇ -Galactosidase A Farber Acid ceramidase Fucosidosis Acid ⁇ -L-fucosidase Gaucher types 1, 2, and 3 Acid ⁇ -glucosidase G M1 gangliosidosis Acid ⁇ -galactosidase Hunter (Mucopolysaccharidosis (MPS) II) Iduronate-2-sulfatase Hurler-Scheie, Hurler, Scheie (MPS I) ⁇ -L-Iduronidase Krabbe Galactocerebrosidase ⁇ -Mannosidosis Acid ⁇ -mannosidase ⁇ -Mannosidosis Acid ⁇ -mannosidase Maroteaux-Lamy (MPS VI) Arylsulfatase B Metachromatic leukodystrophy Arylsulfatase A Morquio A
  • the glycoprotein may be a glycoprotein having at least 1, 2, 3, 4, 5, or more N -linked or O -linked glycosylated amino acid residues. In other embodiments, the protein may have 1, 2, 3, 4, 5 or more consensus sites for N -linked or O -linked glycosylation, at least one of which is glycosylated.
  • the protein may be a ligand for a receptor.
  • the protein may be a glycoprotein that binds to a receptor that recognizes a sugar such as, e.g., mannose or mannose-6-phosphate.
  • the glycoprotein may bind to, e.g., the asialoglycoprotein receptor, the cation-dependent mannose-6-phosphate receptor, the insulin-like growth factor II/cation-independent mannose-6-phosphate receptor, or the macrophage mannose receptor.
  • the protein is a glycoprotein that, when conjugated to an oligosaccharide comprising mannose-6-phosphate, is internalized more efficiently by a target cell (e.g., via CI-MPR-mediated endocytosis) than is the corresponding unconjugated glycoprotein.
  • the conjugated glycoprotein may be internalized more efficiently than the unconjugated glycoprotein by, e.g., at least 10%, 15%, 20%, 25%, 30%, 35%, 40%, 50%, 60%, 70%, 80%, or 90% (w/w) in a given time period.
  • At least 2, 3, 4, 5, 6, 7, 8, 9, or 10 fold (w/w) as much of the conjugated glycoprotein may be internalized, relative to the unconjugated glycoprotein, in a given time period.
  • the referenced time period may be, for example, 10, 30, 45 minutes or 1, 2, 3, 5, 6, 12, 24, 48, or 72 hours, or more.
  • the disclosure provides methods of coupling an oligosaccharide to a protein, such as, e.g. a glycoprotein.
  • the method comprises:
  • the methods further comprise adding a reducing agent to the coupled lysosomal enzyme.
  • the reducing agent may be any reducing agent known to those of skill in the art, such as, e.g., sodium cyanoborohydride or sodium triacetoxyborohydride (STAB).
  • the disclosure further provides an oligosaccharide-protein conjugate, comprising (1) a protein, (2) an oligosaccharide, and (3) an oxime group connecting the protein and the oligosaccharide.
  • the invention provides an oligosaccharide-protein conjugate prepared by the methods disclosed above.
  • the oligosaccharide and protein components of the conjugate may be, for example, any oligosaccharide and protein described herein, wherein a conjugate thereof comprises an oxime group, as depicted below.
  • the oxime group depicted below is formally derived by reaction of an aminooxy group and an aldehyde group; oxime groups formally derived by reaction of an aminooxy group and a ketone group are also encompassed by this invention.
  • the oligosaccharide-protein conjugate is an oligosaccharide-glycoprotein conjugate. In certain embodiments, the oligosaccharide-protein conjugate is the conjugate of an oligosaccharide comprising at least one M6P and a lysosomal hydrolase.
  • compositions comprising an oligosaccharide-protein conjugate of the invention.
  • pharmaceutical compositions of the disclosure comprise a conjugate of an oligosaccharide comprising at least one M6P and a lysosomal enzyme.
  • compositions of the invention may comprise one or more suitable pharmaceutical excipients.
  • Standard pharmaceutical formulation techniques and excipients are well known to persons skilled in the art (see, e.g., 2005 Physicians' Desk Reference®, Thomson Healthcare: Montvale, NJ, 2004 ; Remington: The Science and Practice of Pharmacy, 20th ed., Gennado et al., Eds. Lippincott Williams & Wilkins: Philadelphia, PA, 2000 ).
  • the compositions may or may not contain preservatives.
  • compositions comprising ⁇ -galactosidase A conjugates may comprise one or more excipients such as, e.g., mannitol, sodium phosphate monobasic monohydrate, and/or sodium phosphate dibasic heptahydrate.
  • pharmaceutical compositions comprising conjugates of ⁇ -glucosidase may comprise one or more excipients such as, e.g., mannitol, polysorbate 80, sodium phosphate dibasic heptahydrate, and sodium phosphate monobasic monhydrate.
  • the pharmaceutical composition may comprise any of the conjugates described herein either as the sole active compound or in combination with another compound, composition, or biological material.
  • the pharmaceutical composition may also comprise one or more small molecules useful for the treatment of a LSD and/or a side effect associated with the LSD.
  • the composition may comprise miglustat and/or one or more compounds described in, e.g., U.S. Patent Application Publication Nos. 2003/0050299 , 2003/0153768 ; 2005/0222244 ; 2005/0267094 .
  • compositions may vary depending on the intended route of administrations and other parameters (see, e.g., Rowe et al. Handbook of Pharmaceutical Excipients, 4th ed., APhA Publications, 2003 .)
  • the composition may be a sterile, non-pyrogenic, white to off-white lyophilized cake or powder to be administered by intravenous injection upon reconstitution with Sterile Water for Injection, USP.
  • Administration of a pharmaceutical composition of the invention is not limited to any particular delivery system and may include, without limitation, parenteral (including subcutaneous, intravenous, intracranial, intramedullary, intraarticular, intramuscular, intrathecal, or intraperitoneal injection), transdermal, or oral (for example, in capsules, suspensions, or tablets). Administration to an individual may occur in a single dose or in repeat administrations, and in any of a variety of physiologically acceptable salt forms, and/or with an acceptable pharmaceutical carrier and/or additive as part of a pharmaceutical composition.
  • a therapeutically effective amount may vary with the subject's age, condition, and sex, as well as the severity of the medical condition in the subject.
  • the dosage may be determined by a physician and adjusted, as necessary, to suit observed effects of the treatment. Toxicity and therapeutic efficacy of such compounds can be determined by standard pharmaceutical procedures in vitro (i.e., cell cultures) or in vivo (i.e., experimental animal models), e.g., for determining the LD 50 (the dose lethal to 50% of the population) and the ED 50 (the dose therapeutically effective in 50% of the population).
  • the dose ratio between toxic and therapeutic effects is the therapeutic index (or therapeutic ratio), and can be expressed as the ratio LD 50 /ED 50 .
  • Conjugates that exhibit therapeutic indices of at least 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, and 20 are described herein. Conjugates that exhibit a large therapeutic index are preferred.
  • the data obtained from in vitro assays and animal studies, for example, can be used in formulating a range of dosage for use in humans.
  • the dosage of such compounds lies preferably within a range of circulating concentrations that include the ED 50 with low, little, or no toxicity.
  • the dosage may vary within this range depending upon the dosage form employed and the route of administration utilized.
  • the therapeutically effective dose can be estimated initially from in vitro assays.
  • a dose may be formulated in animal models to achieve a circulating plasma concentration range that includes the IC 50 (i.e., the concentration of the test conjugate which achieves a half-maximal inhibition of symptoms) as determined in in vitro experiments.
  • Levels in plasma may be measured, for example, by high performance liquid chromatography or by an appropriate enzymatic activity assay.
  • the effects of any particular dosage can be monitored by a suitable bioassay of endpoints.
  • conjugates of the invention may be administered at a dose of approximately from 1 ⁇ g/kg to 500 mg/kg, depending on the severity of the symptoms and the progression of the disease.
  • proteinaceous compounds may be administered by slow intravenous infusion in an outpatient setting every, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more days, or by, e.g., weekly, biweekly, monthly, or bimonthly administration.
  • the appropriate therapeutically effective dose of a compound is selected by a treating clinician and would range approximately from 1 ⁇ g/kg to 500 mg/kg, from 1 ⁇ g/kg to 10 mg/kg, from 1 ⁇ g/kg to 1 mg/kg, from 10 ⁇ g/kg to 1 mg/kg, from 10 ⁇ g/kg to 100 ⁇ g/kg, from 100 ⁇ g to 1 mg/kg, and from 500 ⁇ g/kg to 5 mg/kg.
  • conjugates of ⁇ -galactosidase A may be administered by intravenous infusion at a dose of, e.g., 1.0 mg/kg body weight every two weeks at an infusion rate of, e.g., less than or equal to 10, 13, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, or 33 mg/hour).
  • conjugates of ⁇ -glucosidase may be administered by intravenous injection at a dose of, e.g., 20 mg/kg or 40 mg/kg every two weeks, over approximately, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 hours.
  • the rate of administration of ⁇ -glucosidase may be started at, e.g., 1 mg/kg/hr and then increased by, e.g., 2 mg/kg/hr every 30 minutes, after establishing patient tolerance to the infusion rate, until a maximum of, e.g., 7 mg/kg/hr.
  • a maximum of, e.g., 7 mg/kg/hr examples of specific dosages may be found in the Physicians' Desk Reference® .
  • the disclosure provides methods of treating lysosomal storage disorders, such as, e.g., those disclosed in Table 1.
  • the disclosure provides the use of a conjugate described herein for treating a lysosomal storage disorder in a subject in need thereof.
  • the disclosure further provides methods of targeting proteins to the lysosome by conjugation with oligosaccharides comprising mannose-6-phosphate.
  • the method comprises administering to a mammal having a lysosomal storage disorder an oligosaccharide-glycoprotein conjugate of the invention in a therapeutically effective amount.
  • the oligosaccharide-glycoprotein conjugate may be a conjugate of a lysosomal enzyme, such as a lysosomal enzyme listed in Table 1, with an oligosaccharide comprising mannose-6-phosphate.
  • the method comprises administering to a subject in need thereof a pharmaceutical composition comprising at least one of the conjugates described herein.
  • conjugates of the invention may be administered with one or more other therapies.
  • the one or more other therapies may be administered concurrently with (including concurrent administration as a combined formulation), before, or after the administration of the conjugates of the invention.
  • a patient may be treated (before, after, or during treatment with a conjugate of the invention) with an antipyretic, antihistamine, and/or immunosuppressant.
  • a patient may be treated with an antipyretic, antihistamine, and/or immunosuppressant prior to treatment with an oligosaccharide-glycoprotein conjugate of the invention in order to decrease or prevent infusion-associated reactions.
  • patients may be pretreated with one or more of acetaminophen, azathioprine, cyclophosphamide, cyclosporin A, methotrexate, mycophenolate mofetil, oral steroids, or rapamycin.
  • methotrexate e.g., with 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 8, 10, 12, 15, 25, 30, 35, 40, 50, 60, 70, 80 mg/kg methotrexate, or more
  • immune tolerance toward conjugates of the invention may be induced in a patient with a lysosomal storage disorder such as, e.g., mucopolysaccharidosis I, by treatment with cyclosporin A and azathioprine.
  • a lysosomal storage disorder such as, e.g., mucopolysaccharidosis I
  • the patient may be treated with cyclosporine A and azathioprine as described in Kakkis et al., Proc. Natl. Acad. Sci. U.S.A. 101:829-834 (2004 ).
  • a patient may be treated (before, after, or during treatment with a conjugate of the invention) with e.g., small molecule therapy and/or gene therapy, including small molecule therapy and gene therapy directed toward treatment of a lysosomal storage disorder.
  • Small molecule therapy may comprise administration of one or more compounds described in, e.g., U.S. Patent Application Publication Nos. 2003/0050299 , 2003/0153768 ; 2005/0222244 ; and 2005/0267094 .
  • Gene therapy may be performed as described in, e.g., U.S. Patent Nos. 5,952,516 ; 6,066,626 ; 6,071,890 ; and 6,287,857 and U.S. Patent Application Publication No. 2003/0087868 .
  • treatment refers to both therapeutic treatment and prophylactic/preventative measures.
  • those in need of treatment may include individuals already having a particular lysosomal storage disease as well as those at risk for the disease (i.e., those who are likely to ultimately acquire the disorder or certain symptoms of the disorder).
  • a therapeutic method results in the prevention or amelioration of symptoms or an otherwise desired biological outcome, and may be evaluated by improved clinical signs or delayed onset of disease, increased activity of the metabolically defective enzyme, and/or decreased levels of the accumulated substrate of the metabolically defective enzyme.
  • the conjugates of the present invention are useful to treat various lysosomal storage disorders in humans or animals.
  • administration of the conjugates can be used to increase the deficient enzymatic activity in a patient, for example, by at least 10%.
  • the increased enzymatic activity may be determined by, e.g., a reduction in clinical symptoms or by an appropriate clinical or biological assay.
  • GAA conjugates may be administered for the treatment of Pompe disease (also known as acid ⁇ -glucosidase deficiency, acid maltase deficiency, glycogen storage disease type II, glycogenosis II, and lysosomal ⁇ -glucosidase deficiency).
  • Increased GAA activity may be determined by biochemical (see, e.g., Zhu et al., J. Biol. Chem. 279: 50336-50341 (2004 )) or histological observation of reduced lysosomal glycogen accumulation in, e.g., cardiac myocytes, skeletal myocytes, or skin fibroblasts.
  • GAA activity may also be assayed in, e.g., a muscle biopsy sample, in cultured skin fibroblasts, in lymphocytes, and in dried blood spots. Dried blood spot assays are described in e.g., Umpathysivam et al., Clin. Chem. 47:1378-1383 (2001 ) and Li et al., Clin. Chem. 50:1785-1796 (2004 ).
  • Treatment of Pompe disease may also be assessed by, e.g., serum levels of creatinine kinase, gains in motor function (e.g., as assessed by the Alberta Infant Motor Scale), changes in left ventricular mass index as measured by echocardiogram, and cardiac electrical activity, as measured by electrocardiogram.
  • GAA conjugates may result in a reduction in one or more symptoms of Pompe disease such as cardiomegaly, cardiomyopathy, daytime somnolescence, exertional dyspnea, failure to thrive, feeding difficulties, "floppiness,” gait abnormalities, headaches, hypotonia, organomegaly (e.g., enlargement of heart, tongue, liver), lordosis, loss of balance, lower back pain, morning headaches, muscle weakness, respiratory insufficiency, scapular winging, scoliosis, reduced deep tendon reflexes, sleep apnea, susceptibility to respiratory infections, and vomiting.
  • Pompe disease such as cardiomegaly, cardiomyopathy, daytime somnolescence, exertional dyspnea, failure to thrive, feeding difficulties, "floppiness,” gait abnormalities, headaches, hypotonia, organomegaly (e.g., enlargement of heart, tongue, liver), lordosis, loss of balance, lower back pain, morning headaches, muscle weakness,
  • conjugates of a-galactosidase A with oligosaccharides comprising M6P are administered for the treatment of Fabry disease.
  • Fabry disease or Anderson-Fabry disease, is a rare, X-linked, lysosomal storage disorder marked by a deficiency of ⁇ -galactosidase A, and results in accumulation of globotriaosylceramide (GL3) and other neutral glycosphingolipids in the lysosomes of visceral tissues and endothelial, perithelial, and muscle cells. Accumulation of the neutral glycosphingolipids in the vasculature results in narrowing and dilatation of the blood vessels, and ultimately to ischemia and infarction.
  • GL3 globotriaosylceramide
  • ⁇ -galactosidase A conjugates may result in a reduction in one or more clinical symptoms of Fabry disease including, e.g., acroparesthesia, angina, angiokeratoma, arrythmia, ataxia of gait, burning and/or tingling pain in the hands and feet, cataracts, cold intolerance, conduction abnormalities, corneal whorling, coronary artery disease, dementia, depression, diarrhea, dilated cardiac chambers, dizziness, cardiomegaly, cardiomyopathy, diplopia, dysarthria, fatigue, fever with elevated erythrocyte sedimentation rate, hearing problems, heart disease, heart valve problems, heat intolerance, hemiataxia, hemiparesis, hypohidrosis, impaired sweating, infarction, ischemia, joint pain, kidney disease, left ventricular hypertrophy, lenticular abnormalities, lenticular opacity, lipiduria, muscle weakness, myocardial infarction, nausea, nys
  • Administration of ⁇ -galactosidase A conjugates may result in increased ⁇ -galactosidase A activity in, e.g., plasma, tears, leukocytes, biopsied tissues, or cultured skin fibroblasts.
  • Administration of ⁇ -galactosidase A conjugates may also result in a histologic finding of a reduction (e.g., of at least 10%) or lack of increase of birefringent lipid globules. It may also result in a decrease in lipid globules in urinary sediment, improved renal function as measured by serum creatinine levels or creatinine clearance, and reduced proteinuria.
  • ⁇ -galactosidase A conjugates may also result in a reduction in GL3 inclusions in the capillary endothelium of the kidney, heart, and skin. Additional assays for measuring efficacy of treatment for Fabry disease can be found in, e.g., MacDermott et al., J. Med. Genet. 38:750-760 (2001 ).
  • conjugates of acid sphingomyelinase are administered for treatment of Niemann-Pick disease, or acid sphingomyelinase deficiency.
  • Administration of acid sphingomyelinase conjugates may result in a reduction in one or more clinical symptoms of Niemann-Pick disease including, e.g., abnormal cholesterol levels, abnormal lipid levels, ataxia, blood abnormalities, cherry red spots in the eye, frequent lung infections, growth retardation, hepatosplenomegaly, low numbers of platelets, lymphadenopathy, peripheral neuropathy, problems with lung function, shortness of breath, skin pigmentation changes, or xanthomas.
  • conjugates may be administered intracranially.
  • An alternative embodiment relates to treatment of mucopolysaccharidosis I (including, e.g., Hurler and Hurler-Scheie forms of MPS I) with conjugates comprising ⁇ -L-iduronidase.
  • Administration of ⁇ -L-iduronidase conjugates may result in a reduction in one or more clinical symptoms of MPS I including, e.g., aortic regurgitation, aortic stenosis, carpal tunnel syndrome, chronic rhinitis, conductive hearing loss, constipation, corneal clouding, developmental delay, diarrhea, distended abdomen, dorsolumbar kyphosis, gibbus deformity of the back, hepatosplenomegaly, hydrocephalus, inguinal hernia, kyphosis, mental retardation, mitral regurgitation, mitral stenosis, night-blindness, open-angle glaucoma, poor hand function, progressive arthropathy, recurrent respiratory infections, respiratory insufficiency
  • Examples 1-4 below describe the synthetic route depicted in FIG. 1 .
  • Compounds 1 , 2 , 3 , and 4 as used below, have the chemical structures depicted in FIG. 1 .
  • oligosaccharide 1 100 mg was dissolved in 15 ml of DMSO/H 2 O (50:50 in volume), yielding a 5.3 ⁇ mol/ml solution.
  • 100 mg of t-Boc-aminooxy acetic acid tetrafluorophenyl ester 2 (Invitrogen Corp.; Carlsbad, CA; catalog # B3030) was dissolved in 7.5 ml of DMSO.
  • Method A The reaction mixture was diluted with an equal volume of H 2 O and dialyzed in dialysis tubing with molecular weight cutoff of 1000 Dalton (SpectraPor Inc.) twice against 4 L of H 2 O at 4 oC for at least 3 hours each. The samples were then lyophilized.
  • Method B A Sephadex G-10 gel permeation chromatography column with a bed volume of 225 ml was packed and equilibrated with deionized water. The reaction mixture was loaded onto the column, drained by gravity, and then eluted with deionized water at a flow rate of 75 ml per hour. 4.5 ml fractions were collected with a fraction collector. Fractions 10-23, which contained oligosaccharide 3 , were collected, combined and lyophilized. The other small molecules, including t-Boc-AOAA, DHBt-OH, and DMSO, eluted in the later fractions, and were discarded.
  • the t-Boc group of the lyophilized sample was deprotected in 5 ml of 50% trifluoroacetic acid (TFA) in dicholormethane (DCM) in a glass bottle for 30 min with gentle shaking at 100 RPM.
  • TFA/DCM was then removed by a stream of N 2 in a chemical hood.
  • Method A After removing the TFA/DCM, the residue was dissolved in 10 ml of 0.5 M sodium acetate buffer, pH 5, and transferred to dialysis tubing with a molecular weight cutoff of 1000 Dalton. The bottle was washed with 4 ml of the same buffer, which was then transferred to the dialysis tubing. The sample was dialyzed twice against 3 L of 25 mM sodium acetate buffer, pH 7, for at least 3 hours, and then transferred to 4 L ice-cold H 2 O for overnight dialysis. The sample was recovered from the dialysis tubing and lyophilized.
  • Method B After removing the TFA/DCM, the residue was dissolved in 5 ml of 0.5 M sodium acetate buffer, pH 7.5, and loaded onto a Sephadex G-10 gel permeation chromatography column as in Example 2, Method B. The reaction mixture was loaded onto the column, drained by gravity, and then eluted with deionized water at a flow rate of 75 ml per hour. 4.5 ml fractions were collected with a fraction collector. Fractions 10-23, which contained purified oligosaccharide 4 , were collected and lyophilized. A higher yield of oligosaccharide 4 was obtained upon purification by Method B than by Method A.
  • the final product obtained either from method B was analyzed by Dionex chromatography ( FIG. 2C ), and the identity of the product was confirmed by mass spectrometry ( FIG. 3B ). Some impurities were present in the spectra of FIG. 2C and FIG. 3B .
  • rhGAA Lyophilized recombinant human GAA
  • rhGAA Lyophilized recombinant human GAA
  • 4 L 100 mM acetate buffer (pH 5.6) 4 times to completely remove mannitol.
  • the rhGAA was oxidized with 7.5 mM sodium periodate from 100 mM stock in 100 mM acetate buffer.
  • glycerol was added, and the sample was mixed on ice for 10 minutes to decompose excess sodium periodate.
  • the oxidized material was then dialyzed against aqueous buffer (e.g., 100 mM sodium acetate) overnight.
  • aqueous buffer e.g., 100 mM sodium acetate
  • oligosaccharide 4 in aqueous buffer (e.g., 100 mM sodium acetate, pH 5.6) was mixed with oxidized GAA and incubated at 37 oC for 4 hours to yield oligosaccharide-GAA conjugate 5 .
  • the reaction mixture was then diafiltered against 25 mM sodium phosphate buffer, pH 6.25, to remove unconjugated bisM6P glycan, and then adjusted with GAA formulation buffer (25 mM sodium phosphate buffer, pH 6.25, 2% mannitol, 0.005% Tween-80).
  • oligosaccharide conjugation was measured by assaying conjugate 5 for binding to a M6P receptor column to which glycoproteins lacking M6P do not bind.
  • Five micrograms of conjugate 5 were loaded onto a pre-equilibrated CI-MPR-Sepharose column (the column was prepared by coupling CI-MPR isolated from fetal bovine serum to Affigel-10), which was then washed with CI-MPR binding buffer for 11x 2 mL fractions and eluted with CI-MPR binding buffer containing 5 mM M6P for 7x 2mL fractions. A total of 18 fractions were collected and assayed for enzymatic activity.
  • Conjugate 5 is treated with 4N trifluoroacetic acid to hydrolyze the oligosaccharides, followed by high pH anion exchange chromatography with pulsed amperometric detection (PAD) on a BioLC liquid chromatography system (Dionex).
  • PAD pulsed amperometric detection
  • the monosaccharide content is extrapolated from a monosaccharide standard curve using premixed monosaccharide standards (Dionex).
  • GAA activity is measured using a fluorometric assay in black 96-well microplates using 4-methylumbelliferyl- ⁇ -D-glucoside as a substrate. Dilutions of conjugate 5 are added in triplicate to a microtiter plate. 4-methylumbelliferyl- ⁇ -D-glucoside is added to each sample. The 96-well plate is incubated in a 37 °C incubator for 30 minutes. The release of product is detected fluorometrically, and compared to standard curves generated by measuring the fluorescence of a known quantity of a standard. The reaction is quenched by the addition of 125 ⁇ L of 1.0 M glycine-carbonate buffer, pH 10.5 to all wells. The specific activity is defined as nmol product released/hr/mg.
  • L6 Myoblasts Cells (ATCC CRL-1458) were seeded into 6-well plates at 5.0x10 5 cells/well in growth media (DMEM + 10% FBS) and grown to confluency. Cells were incubated with 0-100 nM GAA (conjugate 5 or unconjugated rhGAA) for 16 hours in DMEM + 1% heat-inactivated-FBS + 10 mM Hepes pH 6.7. After uptake, cells were washed with 3x PBS containing 5 mM M6P and lysed with 0.25% Triton X-100 for 1 hour on ice. Lysates were centrifuged at 18000g for 5 minutes and tested for specific activity. See, e.g., Zhu et al., J. Biol. Chem. 279:50336-50341 (2004 ); Zhu et al., Biochem. J. 389:619-628 (2005 ).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Claims (13)

  1. Procédé de préparation d'un oligosaccharide comprenant un groupe aminooxy, le procédé comprenant :
    (a) la fourniture d'un oligosaccharide comprenant un premier groupe réactif, le premier groupe réactif étant un groupe hydrazide ou un groupe carboxyle ;
    (b) la fourniture d'un composé aminooxy comprenant un groupe aminooxy et un deuxième groupe réactif, le deuxième groupe réactif étant choisi parmi des groupes hydrazine, hydrazide, semicarbazide, thiosemicarbazide, amine, carboxyle, ester, halogénure d'acyle, azide d'acyle, halogénure d'alkyle, anhydride, isothiocyanate, isocyanate et halogénure de sulfonyle ; et
    (c) la réaction du premier groupe réactif de l'oligosaccharide avec le deuxième groupe réactif du composé aminooxy,
    de façon à préparer l'oligosaccharide comprenant un groupe aminooxy.
  2. Procédé de la revendication 1, dans lequel le composé aminooxy est choisi parmi des composés de formule II :
    Figure imgb0116
     dans lequel Y est le deuxième groupe réactif, Z est choisi parmi alkyle, alcényle, alcynyle, hétéroaryle, aryle, et hétérocyclyle, et P est choisi parmi des groupes protecteurs d'amino.
  3. Procédé de la revendication 2, dans lequel Y est choisi parmi :
    Figure imgb0117
    Figure imgb0118
    Figure imgb0119
    Figure imgb0120
    Figure imgb0121
    Figure imgb0122
    Figure imgb0123
     et
    Figure imgb0124
     dans lequel X est choisi parmi halogènes, azide, acyloxy, alcoxy, aryloxy, hétéroaryloxy et hétérocyclyloxy.
  4. Procédé de la revendication 2, dans lequel le composé aminooxy est choisi parmi des composés de formule III :
    Figure imgb0125
     dans lequel Y est le deuxième groupe réactif, n est choisi parmi des entiers dans la plage de 1 à 10, et P est choisi parmi des groupes protecteurs d'amino.
  5. Procédé de la revendication 4, dans lequel le composé aminooxy est
    Figure imgb0126
  6. Procédé de la revendication 4, dans lequel le composé aminooxy est
    Figure imgb0127
  7. Procédé de l'une quelconque des revendications 1 à 6, dans lequel l'oligosaccharide est
    Figure imgb0128
     ou
    Figure imgb0129
  8. Procédé de l'une quelconque des revendications 1 à 7, dans lequel le composé aminooxy comprend un groupe protecteur d'amino, le procédé comprenant en outre (d) la déprotection de l'oligosaccharide comprenant un groupe aminooxy.
  9. Procédé de la revendication 1, le procédé comprenant :
    (a) la fourniture d'un oligosaccharide comprenant un premier groupe réactif, l'oligosaccharide étant
    Figure imgb0130
    (b) la fourniture d'un composé aminooxy comprenant un groupe aminooxy et un deuxième groupe réactif, le composé aminooxy étant choisi parmi des composés de formule III :
    Figure imgb0131
     dans lequel n est choisi parmi des entiers dans la plage de 1 à 10, P est choisi parmi des groupes protecteurs d'amino, et Y est le deuxième groupe réactif ; et
    (c) la réaction du premier groupe réactif de l'oligosaccharide avec le deuxième groupe réactif du composé aminooxy, de façon à préparer l'oligosaccharide comprenant un groupe aminooxy.
  10. Procédé de la revendication 9, dans lequel le composé aminooxy est
    Figure imgb0132
  11. Procédé de la revendication 1, le procédé comprenant :
    (a) la fourniture d'un oligosaccharide comprenant un premier groupe réactif, l'oligosaccharide étant
    Figure imgb0133
    (b) la fourniture d'un composé aminooxy comprenant un groupe aminooxy et un deuxième groupe réactif, le composé aminooxy étant choisi parmi des composés de formule III :
    Figure imgb0134
     dans lequel n est choisi parmi des entiers dans la plage de 1 à 10, P est choisi parmi des groupes protecteurs d'amino, et Y est le deuxième groupe réactif ; et
    (c) la réaction du premier groupe réactif de l'oligosaccharide avec le deuxième groupe réactif du composé aminooxy, de façon à préparer l'oligosaccharide comprenant un groupe aminooxy.
  12. Procédé de la revendication 11, dans lequel le composé aminooxy est
    Figure imgb0135
  13. Procédé de la revendication 10 ou 12, dans lequel l'étape (c) comprend la réaction du premier groupe réactif de l'oligosaccharide avec le deuxième groupe réactif du composé aminooxy en présence d'un réactif de couplage et/ou d'un catalyseur.
EP11188504.2A 2007-01-18 2008-01-18 Oligosaccharides comportant un groupe amino-oxy et conjugués associés Active EP2457919B1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP23187944.6A EP4293112A3 (fr) 2007-01-18 2008-01-18 Oligosaccharides comportant un groupe amino-oxy et conjugués associés
EP19177425.6A EP3597655B1 (fr) 2007-01-18 2008-01-18 Oligosaccharides comportant un groupe amino-oxy et conjugués associés
SI200832088T SI2457919T1 (sl) 2007-01-18 2008-01-18 Oligosaharidi, ki vsebujejo skupino aminooksi in njihovi konjugati
PL11188504T PL2457919T3 (pl) 2007-01-18 2008-01-18 Oligosacharydy zawierające grupę aminooksylową i ich koniugaty
HRP20191562 HRP20191562T1 (hr) 2007-01-18 2019-08-30 Oligosaharidi koji sadrže aminooksi skupinu i njihovi konjugati

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US88547107P 2007-01-18 2007-01-18
EP08727910.5A EP2121713B1 (fr) 2007-01-18 2008-01-18 Oligosaccharides comprenant un groupe aminooxy et des conjugués de celui-ci
PCT/US2008/051429 WO2008089403A2 (fr) 2007-01-18 2008-01-18 Oligosaccharides comprenant un groupe aminooxy et des conjugués de celui-ci

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
EP08727910.5A Division EP2121713B1 (fr) 2007-01-18 2008-01-18 Oligosaccharides comprenant un groupe aminooxy et des conjugués de celui-ci
EP08727910.5 Division 2008-01-18

Related Child Applications (2)

Application Number Title Priority Date Filing Date
EP19177425.6A Division EP3597655B1 (fr) 2007-01-18 2008-01-18 Oligosaccharides comportant un groupe amino-oxy et conjugués associés
EP23187944.6A Division EP4293112A3 (fr) 2007-01-18 2008-01-18 Oligosaccharides comportant un groupe amino-oxy et conjugués associés

Publications (2)

Publication Number Publication Date
EP2457919A1 EP2457919A1 (fr) 2012-05-30
EP2457919B1 true EP2457919B1 (fr) 2019-06-05

Family

ID=39473250

Family Applications (5)

Application Number Title Priority Date Filing Date
EP11188504.2A Active EP2457919B1 (fr) 2007-01-18 2008-01-18 Oligosaccharides comportant un groupe amino-oxy et conjugués associés
EP08727910.5A Active EP2121713B1 (fr) 2007-01-18 2008-01-18 Oligosaccharides comprenant un groupe aminooxy et des conjugués de celui-ci
EP23187944.6A Pending EP4293112A3 (fr) 2007-01-18 2008-01-18 Oligosaccharides comportant un groupe amino-oxy et conjugués associés
EP11188506.7A Active EP2457920B1 (fr) 2007-01-18 2008-01-18 Oligosaccharides comportant un groupe amino-oxy et conjugués associés
EP19177425.6A Active EP3597655B1 (fr) 2007-01-18 2008-01-18 Oligosaccharides comportant un groupe amino-oxy et conjugués associés

Family Applications After (4)

Application Number Title Priority Date Filing Date
EP08727910.5A Active EP2121713B1 (fr) 2007-01-18 2008-01-18 Oligosaccharides comprenant un groupe aminooxy et des conjugués de celui-ci
EP23187944.6A Pending EP4293112A3 (fr) 2007-01-18 2008-01-18 Oligosaccharides comportant un groupe amino-oxy et conjugués associés
EP11188506.7A Active EP2457920B1 (fr) 2007-01-18 2008-01-18 Oligosaccharides comportant un groupe amino-oxy et conjugués associés
EP19177425.6A Active EP3597655B1 (fr) 2007-01-18 2008-01-18 Oligosaccharides comportant un groupe amino-oxy et conjugués associés

Country Status (19)

Country Link
US (5) US8759501B2 (fr)
EP (5) EP2457919B1 (fr)
JP (6) JP5999867B2 (fr)
CN (2) CN102978185B (fr)
CA (1) CA2675968C (fr)
CY (2) CY1119954T1 (fr)
DK (3) DK2457920T3 (fr)
ES (3) ES2417146T3 (fr)
FR (1) FR22C1061I2 (fr)
HR (3) HRP20130744T1 (fr)
HU (3) HUE045046T2 (fr)
IL (3) IL243117B2 (fr)
LT (2) LT2457919T (fr)
NL (1) NL301210I2 (fr)
NO (2) NO2457920T3 (fr)
PL (3) PL2457920T3 (fr)
PT (3) PT2457920T (fr)
SI (2) SI2457919T1 (fr)
WO (1) WO2008089403A2 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723296B2 (en) 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
WO2008013735A2 (fr) * 2006-07-21 2008-01-31 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Procédés de conjugaison d'oligosaccharides ou de polysaccharides à des supports protéiques par des liaisons oxime au moyen d'acides 3-désoxy-d-manno-octulsoniques
DK2457920T3 (en) 2007-01-18 2018-01-22 Genzyme Corp Oligosaccharides comprising an amino oxy group and conjugates thereof
CA2696699A1 (fr) 2007-08-20 2009-02-26 Protalix Ltd. Conjugues de proteines contenant un saccharide et leurs utilisations
US8835614B2 (en) * 2008-12-16 2014-09-16 Genzyme Corporation Oligosaccharide-protein conjugates
WO2011000958A1 (fr) 2009-07-03 2011-01-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Composés ciblant le récepteur du mannose 6-phosphate cation indépendant
SG10201401194VA (en) * 2009-07-27 2014-07-30 Lipoxen Technologies Ltd Glycopolysialylation of non-blood coagulation proteins
AU2010277438B2 (en) 2009-07-27 2015-08-20 Baxalta GmbH Glycopolysialylation of non-blood coagulation proteins
US9194011B2 (en) 2009-11-17 2015-11-24 Protalix Ltd. Stabilized alpha-galactosidase and uses thereof
WO2011163568A1 (fr) * 2010-06-24 2011-12-29 University Of Kansas Conjugués comportant une liaison n-oxime et procédés associés
WO2012082635A1 (fr) * 2010-12-13 2012-06-21 Ancora Pharmaceuticals, Inc. Streptocoque du groupe a à base d'oligosaccharides synthétiques
JP5913372B2 (ja) 2011-01-20 2016-04-27 プロタリクス リミテッド 植物および植物細胞におけるα−ガラクトシダーゼの発現のための核酸発現構築物
WO2014130723A1 (fr) 2013-02-20 2014-08-28 Valerion Therapeutics, Llc Méthodes et compositions pour le traitement de la maladie de pompe
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
TWI821227B (zh) 2017-12-22 2023-11-11 美商健臻公司 胺甲喋呤誘發的免疫耐受性之生物標記
EP3877424A2 (fr) * 2018-11-08 2021-09-15 Kaleido Biosciences, Inc. Compositions oligosaccharidiques et leurs procédés d'utilisation
JP2023513168A (ja) 2020-02-07 2023-03-30 ノバルティス アーゲー 標的化された血漿タンパク質分解
EP4100120A1 (fr) 2020-02-08 2022-12-14 Genzyme Corporation Compositions et méthodes de traitement de la maladie de pompe
WO2021257409A1 (fr) 2020-06-14 2021-12-23 Genzyme Corporation Compositions et méthodes de traitement de la maladie de pompe tardive

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4701521A (en) * 1978-07-17 1987-10-20 The Trustees Of Boston University Method of effecting cellular uptake of molecules
DE2940845B1 (de) 1979-10-09 1980-06-26 Ford Werke Ag Kreiselpumpendichtung,insbesondere fuer Kuehlwasserpumpen in Kraftfahrzeugen
US4671958A (en) * 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US5066789A (en) * 1988-09-30 1991-11-19 Neorx Corporation Targeting substance-diagnostic/therapeutic agent conjugates having Schiff base linkages
IL93432A (en) 1989-02-24 1994-02-27 Johnson Mathey Inc Hydrazines and hydrazides, their conjugates with macromolecules, and such conjugates labeled with metallic ions
US5206370A (en) * 1989-02-24 1993-04-27 Johnson Matthey, Inc. Certain pyridyl hydrazines and hydrazides useful for protein labeling
US5280113A (en) * 1989-08-16 1994-01-18 Monsanto Company Method for producing synthetic N-linked glycoconjugates
US5212298A (en) * 1989-08-16 1993-05-18 Monsanto Company Method for producing synthetic N-linked glycoconjugates
US5324663A (en) * 1990-02-14 1994-06-28 The Regents Of The University Of Michigan Methods and products for the synthesis of oligosaccharide structures on glycoproteins, glycolipids, or as free molecules, and for the isolation of cloned genetic sequences that determine these structures
US5583042A (en) * 1990-04-16 1996-12-10 Neose Pharmaceuticals, Inc. Apparatus for the synthesis of saccharide compositions
US5153312A (en) * 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
CA2073511A1 (fr) * 1990-11-14 1992-05-29 Matthew R. Callstrom Produits de conjugaison entre un poly(vinylglucide) et des proteines dans le but de stabiliser les proteines
WO1992016212A1 (fr) * 1991-03-13 1992-10-01 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce Augmentation de l'efficacite therapeutique d'agents therapeutiques visant des macrophages par regulation positive de la lectine de mannose sur des macrophages
AU1676992A (en) 1991-03-18 1992-10-21 Enzon, Inc. Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers
FR2721612B1 (fr) * 1994-06-23 1996-08-09 Idm Nouveaux dérivés d'oligosides, leur procédé de préparation et leurs applications.
US6132764A (en) * 1994-08-05 2000-10-17 Targesome, Inc. Targeted polymerized liposome diagnostic and treatment agents
US6071890A (en) 1994-12-09 2000-06-06 Genzyme Corporation Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy
US6118045A (en) * 1995-08-02 2000-09-12 Pharming B.V. Lysosomal proteins produced in the milk of transgenic animals
AUPO190596A0 (en) * 1996-08-26 1996-09-19 Alchemia Pty Ltd Oligosaccharide synthesis
ATE451124T1 (de) * 1997-01-21 2009-12-15 Sanofi Pasteur Polysaccharid-peptid-konjugate
US5952516A (en) 1997-05-08 1999-09-14 Genzyme Corporation Cationic amphiphiles containing multiplesteroid lipophilic groups
WO2000009153A1 (fr) 1997-10-29 2000-02-24 Genzyme Corporation Compositions et procedes pour traiter les maladies lysosomiales
US6287857B1 (en) 1998-02-09 2001-09-11 Genzyme Corporation Nucleic acid delivery vehicles
US6538117B1 (en) * 1999-08-10 2003-03-25 The Scripps Research Institute Programmable one-pot oligosaccharide synthesis
AU771330B2 (en) * 1998-08-19 2004-03-18 Baxter Healthcare Sa Immunogenic beta-propionamido-linked polysaccharide protein conjugate useful as a vaccine produced using an N-acryloylated polysaccharide
US6399575B1 (en) * 1998-11-10 2002-06-04 Auburn University Methods and compositions for targeting compounds to the central nervous system
EP1035137A1 (fr) 1999-03-12 2000-09-13 Pasteur Merieux Serums Et Vaccins Procédé d'amination réductrice des polysaccharides
CA2376057A1 (fr) * 1999-06-08 2000-12-14 La Jolla Pharmaceutical Company Molecules a plate-forme de valences comportant des groupes amino-oxy
US6770468B1 (en) * 1999-09-14 2004-08-03 Genzyme Glycobiology Research Institute, Inc. Phosphodiester-α-GlcNAcase of the lysosomal targeting pathway
US6642038B1 (en) * 1999-09-14 2003-11-04 Genzyme Glycobiology Research Institute, Inc. GlcNAc phosphotransferase of the lysosomal targeting pathway
JP2003522806A (ja) 2000-02-15 2003-07-29 ジェンザイム、コーポレーション 改良された薬物送達のための生体高分子の修飾
US6749865B2 (en) * 2000-02-15 2004-06-15 Genzyme Corporation Modification of biopolymers for improved drug delivery
US20040067527A1 (en) 2000-07-26 2004-04-08 Sara Lavi Intracellular delivery system for protein phosphatases and other polypeptides
AU2001286539B2 (en) * 2000-08-18 2007-01-04 Massachusetts Institute Of Technology Apparatus and methods for the automated synthesis of oligosaccharides
US6676963B1 (en) * 2000-10-27 2004-01-13 Barnes-Jewish Hospital Ligand-targeted emulsions carrying bioactive agents
US7723296B2 (en) 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
US7001994B2 (en) 2001-01-18 2006-02-21 Genzyme Corporation Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins
ATE384736T1 (de) * 2001-04-30 2008-02-15 Zystor Therapeutics Inc Subzelluläres targeting von therapeutischen proteinen
US7560424B2 (en) * 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US7629309B2 (en) * 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
CA2408387A1 (fr) 2001-05-07 2001-11-29 Lioudmila Tchistiakova Ligand pour ameliorer l'administration d'agents biologiques par voie orale et via le systeme nerveux central
ES2399323T3 (es) * 2001-07-16 2013-03-27 Genzyme Corporation Síntesis de inhibidores de la UDP-glucosa:N-acilesfingosina glucosiltransferasa
US7265084B2 (en) * 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
DK1578771T3 (da) 2001-10-10 2013-06-10 Novo Nordisk As Remodellering og glycokonjugering af peptider
WO2003045928A1 (fr) 2001-11-26 2003-06-05 Genzyme Corporation Synthese diastereoselective d'udp-glucose : inhibiteurs de la n-acylsphingosine glucosyltransferase
US6905856B2 (en) * 2001-12-21 2005-06-14 Genzyme Glycobiology Research Institute, Inc. Soluble GlcNAc phosphotransferase
US6800472B2 (en) * 2001-12-21 2004-10-05 Genzyme Glycobiology Research Institute, Inc. Expression of lysosomal hydrolase in cells expressing pro-N-acetylglucosamine-1-phosphodiester α-N-acetyl glucosimanidase
JP2006506317A (ja) 2002-01-11 2006-02-23 バイオマリン ファーマシューティカル インコーポレイテッド 治療用リソソーム酵素の送達のための酵素送達系としてのｐ９７の使用
TWI295483B (en) 2002-01-31 2008-04-01 Sumitomo Chemical Co 3-5 group compound semiconductor, process for producing the same, and compound semiconductor element using the same
ATE441706T1 (de) * 2002-02-20 2009-09-15 Gen Hospital Corp Konjugate mit biologisch abbaubarem polymer und verwendung dafür
US6916802B2 (en) 2002-04-29 2005-07-12 Genzyme Corporation Amino ceramide-like compounds and therapeutic methods of use
BR0314106A (pt) 2002-09-11 2005-07-19 Fresenius Kabi De Gmbh Polipeptìdeos hasilados, especialmente eritropoietina hasilada
EP1400533A1 (fr) * 2002-09-11 2004-03-24 Fresenius Kabi Deutschland GmbH Polypeptides hasylés, érythropoiétine hasylée en particulier
WO2005002515A2 (fr) 2003-06-20 2005-01-13 Biomarin Pharmaceutical Inc. Administration de composes therapeutiques au cerveau et a d'autres tissus
US20050026823A1 (en) * 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
EP1654004A2 (fr) 2003-08-08 2006-05-10 Novo Nordisk A/S Synthese et utilisation de nouveaux polymeres ramifies structuraux bien definis comme agents de conjugaison de peptides
JP2007501888A (ja) 2003-08-12 2007-02-01 リポクセン テクノロジーズ リミテッド ポリシアル酸誘導体
US7442372B2 (en) * 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
EP1525890A1 (fr) 2003-10-02 2005-04-27 Complex Biosystems GmbH Complexes protéine-protéophore
US7176185B2 (en) * 2003-11-25 2007-02-13 Tsrl, Inc. Short peptide carrier system for cellular delivery of agent
EP1713508A2 (fr) * 2004-01-29 2006-10-25 Biosynexus Incorporated Utilisation de groupes fonctionnels amino-oxy dans la preparation de vaccins
AU2005211775B2 (en) 2004-02-06 2009-10-08 Biomarin Pharmaceutical Inc. Manufacture of highly phosphorylated lysosomal enzymes and uses thereof
PL1740204T3 (pl) 2004-04-01 2018-08-31 Chiesi Farmaceutici S.P.A. Lecznicze zastosowanie alfa-mannozydazy
US8017151B2 (en) * 2004-09-07 2011-09-13 Board Of Regents Of The University Of Nebraska By And Behalf Of The University Of Nebraska Medical Center Amphiphilic polymer-protein conjugates and methods of use thereof
EP1877099B1 (fr) 2005-04-06 2012-09-19 Genzyme Corporation Conjugués thérapeutiques comprenant une enzyme lysosomale, l'acide polysialique et un agent de ciblage
DK2457920T3 (en) 2007-01-18 2018-01-22 Genzyme Corp Oligosaccharides comprising an amino oxy group and conjugates thereof
WO2008089339A2 (fr) 2007-01-18 2008-07-24 Genzyme Corporation Conjugués d'oligosaccharides utilisés pour le ciblage cellulaire
US8835614B2 (en) * 2008-12-16 2014-09-16 Genzyme Corporation Oligosaccharide-protein conjugates

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None *

Also Published As

Publication number Publication date
EP2121713B1 (fr) 2013-06-12
EP2457920A1 (fr) 2012-05-30
PL2457919T3 (pl) 2019-12-31
CA2675968C (fr) 2019-05-21
IL199925A (en) 2017-09-28
JP2010516257A (ja) 2010-05-20
WO2008089403A2 (fr) 2008-07-24
LT2457920T (lt) 2018-02-12
DK2457920T3 (en) 2018-01-22
PL2121713T3 (pl) 2013-11-29
US8759501B2 (en) 2014-06-24
WO2008089403A3 (fr) 2008-11-13
JP6039625B2 (ja) 2016-12-07
EP3597655A1 (fr) 2020-01-22
SI2457919T1 (sl) 2019-10-30
JP2018109194A (ja) 2018-07-12
EP3597655B1 (fr) 2023-08-02
JP2020185011A (ja) 2020-11-19
US20200010825A1 (en) 2020-01-09
NO2457920T3 (fr) 2018-03-24
EP2121713A2 (fr) 2009-11-25
HRP20130744T1 (hr) 2013-10-11
DK2457919T3 (da) 2019-09-16
EP4293112A3 (fr) 2024-03-13
IL243117B2 (en) 2023-03-01
ES2656314T3 (es) 2018-02-26
CY1119954T1 (el) 2018-12-12
IL243117A (fr) 2016-01-31
FR22C1061I1 (fr) 2023-02-03
US20170014520A1 (en) 2017-01-19
PT2121713E (pt) 2013-06-25
CN101631794A (zh) 2010-01-20
US20100047225A1 (en) 2010-02-25
US20220204963A1 (en) 2022-06-30
CA2675968A1 (fr) 2008-07-24
US10907142B2 (en) 2021-02-02
PT2457920T (pt) 2018-01-23
NL301210I1 (nl) 2022-12-21
EP4293112A2 (fr) 2023-12-20
HRP20180076T1 (hr) 2018-02-23
HRP20191562T1 (hr) 2019-11-29
IL199925A0 (en) 2010-04-15
FR22C1061I2 (fr) 2023-11-17
HUE045046T2 (hu) 2019-12-30
IL222792A0 (en) 2012-12-31
PT2457919T (pt) 2019-09-20
LT2457919T (lt) 2019-09-25
CN102978185B (zh) 2015-02-11
US20150050262A1 (en) 2015-02-19
JP6309592B2 (ja) 2018-04-11
CN101631794B (zh) 2013-01-02
CY1122452T1 (el) 2021-01-27
JP5999867B2 (ja) 2016-09-28
ES2417146T3 (es) 2013-08-06
JP2017052962A (ja) 2017-03-16
ES2744574T3 (es) 2020-02-25
HUS2200055I1 (hu) 2023-01-28
NO2022056I1 (no) 2022-12-09
DK2121713T3 (da) 2013-06-24
JP2015078360A (ja) 2015-04-23
EP2457920B1 (fr) 2017-10-25
PL2457920T3 (pl) 2018-03-30
IL243117B (en) 2022-11-01
US9469850B2 (en) 2016-10-18
JP2022137232A (ja) 2022-09-21
SI2457920T1 (en) 2018-02-28
NL301210I2 (nl) 2023-02-02
EP2457919A1 (fr) 2012-05-30
CN102978185A (zh) 2013-03-20
HUE036140T2 (hu) 2018-06-28

Similar Documents

Publication Publication Date Title
US20220204963A1 (en) Oligosaccharides comprising an aminooxy group and conjugates thereof
US20220242899A1 (en) Oligosaccharide-protein conjugates

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AC Divisional application: reference to earlier application

Ref document number: 2121713

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

17P Request for examination filed

Effective date: 20121129

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1171758

Country of ref document: HK

17Q First examination report despatched

Effective date: 20160512

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

RIC1 Information provided on ipc code assigned before grant

Ipc: C07H 15/04 20060101AFI20180207BHEP

Ipc: A61K 31/738 20060101ALI20180207BHEP

Ipc: A61P 43/00 20060101ALI20180207BHEP

INTG Intention to grant announced

Effective date: 20180309

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: GENZYME CORPORATION

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

INTC Intention to grant announced (deleted)
GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20181219

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AC Divisional application: reference to earlier application

Ref document number: 2121713

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1139867

Country of ref document: AT

Kind code of ref document: T

Effective date: 20190615

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602008060304

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: HR

Ref legal event code: TUEP

Ref document number: P20191562T

Country of ref document: HR

Ref country code: CH

Ref legal event code: PK

Free format text: BERICHTIGUNGEN

REG Reference to a national code

Ref country code: RO

Ref legal event code: EPE

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20190912

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Ref document number: 2457919

Country of ref document: PT

Date of ref document: 20190920

Kind code of ref document: T

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20190903

RIN2 Information on inventor provided after grant (corrected)

Inventor name: AVILA, LUIS Z.

Inventor name: ZHU, YUNXIANG

Inventor name: CHENG, SENG H.

Inventor name: JIANG, CANWEN

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: EE

Ref legal event code: FG4A

Ref document number: E017960

Country of ref document: EE

Effective date: 20190903

REG Reference to a national code

Ref country code: NO

Ref legal event code: T2

Effective date: 20190605

REG Reference to a national code

Ref country code: HR

Ref legal event code: T1PR

Ref document number: P20191562

Country of ref document: HR

REG Reference to a national code

Ref country code: SK

Ref legal event code: T3

Ref document number: E 32019

Country of ref document: SK

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E045046

Country of ref document: HU

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20191562

Country of ref document: HR

Payment date: 20191217

Year of fee payment: 13

Ref country code: GR

Ref legal event code: EP

Ref document number: 20190402701

Country of ref document: GR

Effective date: 20191128

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: RO

Payment date: 20191218

Year of fee payment: 13

Ref country code: LT

Payment date: 20191212

Year of fee payment: 13

Ref country code: SK

Payment date: 20191211

Year of fee payment: 13

Ref country code: MC

Payment date: 20191230

Year of fee payment: 13

Ref country code: BG

Payment date: 20191217

Year of fee payment: 13

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2744574

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20200225

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LV

Payment date: 20191220

Year of fee payment: 13

Ref country code: EE

Payment date: 20191204

Year of fee payment: 13

Ref country code: GR

Payment date: 20191217

Year of fee payment: 13

Ref country code: PL

Payment date: 20191213

Year of fee payment: 13

Ref country code: HR

Payment date: 20191217

Year of fee payment: 13

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602008060304

Country of ref document: DE

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PT

Payment date: 20200117

Year of fee payment: 13

Ref country code: FI

Payment date: 20200109

Year of fee payment: 13

26N No opposition filed

Effective date: 20200306

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20200110

Year of fee payment: 13

Ref country code: SI

Payment date: 20191230

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20200117

Year of fee payment: 13

Ref country code: MT

Payment date: 20200117

Year of fee payment: 13

REG Reference to a national code

Ref country code: HR

Ref legal event code: PBON

Ref document number: P20191562

Country of ref document: HR

Effective date: 20210118

REG Reference to a national code

Ref country code: FI

Ref legal event code: MAE

REG Reference to a national code

Ref country code: EE

Ref legal event code: MM4A

Ref document number: E017960

Country of ref document: EE

Effective date: 20210131

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210201

REG Reference to a national code

Ref country code: SK

Ref legal event code: MM4A

Ref document number: E 32019

Country of ref document: SK

Effective date: 20210118

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210118

REG Reference to a national code

Ref country code: LT

Ref legal event code: MM4D

Effective date: 20210118

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210731

Ref country code: HR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210118

Ref country code: FI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210118

Ref country code: EE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210131

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210805

Ref country code: LV

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210118

Ref country code: RO

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210118

Ref country code: SK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210118

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210719

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210118

REG Reference to a national code

Ref country code: SI

Ref legal event code: KO00

Effective date: 20211130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210119

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210118

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210118

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230424

REG Reference to a national code

Ref country code: AT

Ref legal event code: UEP

Ref document number: 1139867

Country of ref document: AT

Kind code of ref document: T

Effective date: 20190605

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20231130

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20231213

Year of fee payment: 17

Ref country code: NL

Payment date: 20231215

Year of fee payment: 17

Ref country code: IE

Payment date: 20231211

Year of fee payment: 17

Ref country code: FR

Payment date: 20231212

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20231219

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20240206

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20231227

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: HU

Payment date: 20231213

Year of fee payment: 17

Ref country code: DE

Payment date: 20231205

Year of fee payment: 17

Ref country code: CZ

Payment date: 20240103

Year of fee payment: 17

Ref country code: CY

Payment date: 20240117

Year of fee payment: 17

Ref country code: CH

Payment date: 20240201

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NO

Payment date: 20240108

Year of fee payment: 17

Ref country code: IT

Payment date: 20231212

Year of fee payment: 17

Ref country code: DK

Payment date: 20240111

Year of fee payment: 17